RE:Our competition and somewhat good news. MEDIF update us pls.
Please keep in mind that while there may well be exciting future drugs based on cannabinoids, the trial you reference is only a Phase II and has a very long way to go before commercialization; quite possibly 5-7 years with the time needed to finish the current Phase II, plan, recuit and conduct a Phase III and then actually submit a NDA with the review times required with that.
While there are those that have blathered on about late stage this or that with respect to trials, the company itself has issued in both release and MD&A form a summary of their activities and none should be expected prior to the end of the decade. That's not to say that there isn't substantial uptick potential with a bunch of activities currently, but a true NDA submission is LABS 3.0, and we're not even in a mature LABS 2.0 stage yet.
Personally if all goes to as leadership has presented, I doubt LABS exists as a standalone entity at that point any longer.